Article Versions Notes

Kang MK, Song JE, Jang SY, Kim BS, Chung WJ, Lee C, Park SY, Tak WY, Kweon YO, Hwang JS, et al. The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers. 2024; 16(2):454. https://doi.org/10.3390/cancers16020454

Kang, Min Kyu, Jeong Eun Song, Se Young Jang, Byung Seok Kim, Woo Jin Chung, Changhyeong Lee, Soo Young Park, Won Young Tak, Young Oh Kweon, Jae Seok Hwang, and et al. 2024. "The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib" Cancers 16, no. 2: 454. https://doi.org/10.3390/cancers16020454

Kang, M. K., Song, J. E., Jang, S. Y., Kim, B. S., Chung, W. J., Lee, C., Park, S. Y., Tak, W. Y., Kweon, Y. O., Hwang, J. S., Jang, B. K., Lee, Y. R., Park, J. G., & on behalf of Daegu-Gyeongbuk Liver Study Group (DGLSG). (2024). The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers, 16(2), 454. https://doi.org/10.3390/cancers16020454